<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05044390</url>
  </required_header>
  <id_info>
    <org_study_id>420</org_study_id>
    <nct_id>NCT05044390</nct_id>
  </id_info>
  <brief_title>Lung Transplantation for Pleuroparenchymal Fibroelastosis</brief_title>
  <official_title>Lung Transplantation for Pleuroparenchymal Fibroelastosis : a French Multicentric Retrospective Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospices Civils de Lyon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospices Civils de Lyon</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This retrospective observational study will evaluate the outcomes of lung transplantation for&#xD;
      a rare cause of interstitial lung disease called pleuroparenchymal fibroelastosis. Data will&#xD;
      be collected from all transplantation center in France.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 1, 2021</start_date>
  <completion_date type="Anticipated">November 1, 2021</completion_date>
  <primary_completion_date type="Actual">July 1, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Post-operative mortality</measure>
    <time_frame>Any death up to 90 days after lung transplantation</time_frame>
    <description>Any death after lung transplantation during the first 30 days or during the hospitalization following the lung transplantation (in-hospital mortality)</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Fibroelastosis</condition>
  <arm_group>
    <arm_group_label>lung transplantation</arm_group_label>
    <description>Lung transplantation performed for end-stage interstitial lung disease secondary to pleuroparenchymal fibroelastosis.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Lung transplantation (single, lobar or bilateral lung transplantation)</intervention_name>
    <description>Lung transplantation were performed for end-stage interstitial lung disease secondary to pleuroparenchymal fibroelastosis</description>
    <arm_group_label>lung transplantation</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients diagnosed with pleuroparenchymal fibroelastosis who underwent lung transplantation&#xD;
        in France between 2005 and 2021.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Lung transplantation (any type) for pleuroparenchymal fibroelastosis&#xD;
&#xD;
          -  Histologically confirmed pleuroparenchymal fibroelastosis on the recipient lungs&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  All other interstitial lung disease than pleuroparenchymal fibroelastosis&#xD;
&#xD;
          -  Pleuroparenchymal fibroelastosis who didn't underwent lung transplantation&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Marie Lannelongue Hospital</name>
      <address>
        <city>Le Plessis-Robinson</city>
        <zip>92350</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>: Elie FADEL : Elie FADEL, MD</last_name>
      <phone>33 1 40 94 28 00</phone>
      <email>e.fadel@ghpsj.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hopital Louis Pradel</name>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Bichat Claude Bernard Hospital, APHP</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pierre MORDANT, MD</last_name>
      <phone>+ 33 1 40 25 64 40</phone>
      <email>pierre.mordant@aphp.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Foch Hospital</name>
      <address>
        <city>Suresnes</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Edouard SAGE Edouard SAGE, MD</last_name>
      <phone>: +33 1 46 25 28 26</phone>
      <email>e.sage@hopital-foch.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>August 30, 2021</study_first_submitted>
  <study_first_submitted_qc>September 6, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 14, 2021</study_first_posted>
  <last_update_submitted>September 6, 2021</last_update_submitted>
  <last_update_submitted_qc>September 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

